<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytotoxic agents have long been used in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome, especially for eye involvement, but their effectiveness has been uncertain </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a two-year randomized, placebo-controlled, double-blind trial of <z:chebi fb="2" ids="2948">azathioprine</z:chebi> (2.5 mg per kilogram of body weight per day) in Turkish men with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome without <z:e sem="disease" ids="C0015397" disease_type="Disease or Syndrome" abbrv="">eye disease</z:e> (group 1; n = 25) or with <z:e sem="disease" ids="C0015397" disease_type="Disease or Syndrome" abbrv="">eye disease</z:e> (group 2; n = 48) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="50858">Corticosteroid</z:chebi> treatment remained available to <z:hpo ids='HP_0000001'>all</z:hpo> the patients </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> six patients withdrawn from the study because of severe <z:e sem="disease" ids="C0015397" disease_type="Disease or Syndrome" abbrv="">eye disease</z:e> were receiving placebo (P less than 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="2" ids="2948">Azathioprine</z:chebi> was superior to placebo in the prevention of new <z:e sem="disease" ids="C0015397" disease_type="Disease or Syndrome" abbrv="">eye disease</z:e> in group 1 (1 vs. 8 patients; P less than 0.01) and in group 2 among the 14 patients who at entry had disease in only <z:mp ids='MP_0005163'>one eye</z:mp> (P less than 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>There were fewer episodes of <z:e sem="disease" ids="C0020641" disease_type="Disease or Syndrome" abbrv="">hypopyon</z:e> <z:hpo ids='HP_0000554'>uveitis</z:hpo> (1 vs. 15; P less than 0.001) among the group 2 patients who took <z:chebi fb="2" ids="2948">azathioprine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The patients taking <z:chebi fb="2" ids="2948">azathioprine</z:chebi> also had less frequent <z:hpo ids='HP_0000155'>oral ulcers</z:hpo>, <z:hpo ids='HP_0003249'>genital ulcers</z:hpo>, and <z:hpo ids='HP_0001369'>arthritis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>There were no serious side effects attributable to <z:chebi fb="2" ids="2948">azathioprine</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that <z:chebi fb="2" ids="2948">azathioprine</z:chebi> is effective in controlling the progression of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome, especially its most serious manifestation, <z:e sem="disease" ids="C0015397" disease_type="Disease or Syndrome" abbrv="">eye disease</z:e> </plain></SENT>
</text></document>